Glucose-6-phosphate isomerase (GPI), also known as phosphoglucose isomerase (PGI) or autocrine motility factor (AMF), is a dual-function protein. Intracellularly, it plays a key role in glycolysis and gluconeogenesis. Extracellularly, it acts as a cytokine and angiogenic factor (AMF) that stimulates cell migration and metastasis, and serves as a major autoantigen in rheumatoid arthritis (RA) models. Consequently, GPI is a critical target for both oncology and autoimmune disease therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GPI drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPI Recombinant Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. HEK293 or E. coli expressed options. |
View GPI Products |
| Gene Delivery | GPI Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View GPI Products |
| Benchmark Ab | Anti-GPI Recombinant Antibody Sequence-derived recombinant positive control antibody for assay benchmark. |
View GPI Products |
| Validator | GPI siRNA Set Target-specific siRNA pool for gene knockdown and target specificity validation. |
View GPI Products |
| Related Target A | AMFR (GP78) The cell-surface receptor for extracellular GPI/AMF, crucial for studying downstream metastatic signaling. |
View AMFR Products |
| Related Target B | TNF-alpha Key inflammatory cytokine synergistic with GPI-induced autoimmune and arthritis pathways. |
View TNF-alpha Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing enzymatic inhibition from cytokine blocking | Sequence-verified human and rodent ortholog proteins with high conformational integrity, suitable for parallel enzymatic and binding assays. |
| Immunological assay background and endotoxin interference | Strictly endotoxin-controlled recombinant proteins (<1.0 EU/μg) to prevent non-specific immune activation in cell-based assays. |
| Lack of Controls | Clinical-grade recombinant benchmark antibodies included for assay standardization. |
| False Positives | Sequence-verified siRNA pool included for target-specific knockdown verification. |
Live GPI R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GPI is bifurcated into oncology and immunology. In oncology, the focus is on blocking extracellular autocrine motility factor (AMF) signaling via monoclonal antibodies or small molecule inhibitors to halt metastasis and epithelial-mesenchymal transition (EMT). In immunology, GPI is a prominent autoantigen used to study B-cell and T-cell mediated autoimmune responses in rheumatoid arthritis. As first-generation inhibitors of the AMF-AMFR axis enter preclinical and early clinical validation, the next wave of R&D is targeting the specific conformational changes that transition GPI from an intracellular enzyme to an extracellular cytokine.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biotech Startups | Metastatic Solid Tumors, Rheumatoid Arthritis | Epitope mapping and binding affinity assays (Requires high-purity, natively folded GPI antigen) |
| Small Molecule Inhibitors | Oncology-focused Biopharma | Refractory Cancers, Glycolytic-driven Tumors | High-throughput enzymatic screening (Requires sequence-verified, enzymatically active recombinant GPI) |
| siRNA / RNAi Therapeutics | RNAi Therapeutics Developers | Advanced Solid Tumors | In vitro knockdown validation (Requires sequence-verified siRNA and stable overexpressing lentivirus) |